{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:52:26Z","timestamp":1790679146485,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T00:00:00Z","timestamp":1237507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00213-009-1506-7","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T02:30:09Z","timestamp":1237429809000},"page":"171-174","source":"Crossref","is-referenced-by-count":150,"title":["The future of endocannabinoid-oriented clinical research after CB1 antagonists"],"prefix":"10.1007","volume":"205","author":[{"given":"Bernard","family":"Le Foll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,20]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"crossref","first-page":"H595","DOI":"10.1152\/ajpheart.00184.2004","volume":"287","author":"S Batkai","year":"2004","unstructured":"Batkai S, Pacher P, Jarai Z, Wagner JA, Kunos G (2004) Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287:H595\u2013H600","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1506_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.277.5329.1094","volume":"277","author":"M Beltramo","year":"1997","unstructured":"Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094\u20131097","journal-title":"Science"},{"key":"1506_CR3","doi-asserted-by":"crossref","unstructured":"Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev Issue 4. Art. No.: CD005353. doi: 10.1002\/14651858.CD005353.pub3","DOI":"10.1002\/14651858.CD005353.pub3"},{"key":"1506_CR4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706\u20131713","journal-title":"Lancet"},{"key":"1506_CR5","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121\u20132134","journal-title":"N Engl J Med"},{"key":"1506_CR6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","volume":"29","author":"JP Despres","year":"2008","unstructured":"Despres JP, Ross R, Boka G, Almeras N, Lemieux I (2008) Effect of rimonabant on the high-triglyceride\/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat. The ADAGIO-Lipids Trial. Arterioscler Thromb Vasc Biol 29:416","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1506_CR7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tips.2005.06.002","volume":"26","author":"TJ Vries De","year":"2005","unstructured":"De Vries TJ, Schoffelmeer AN (2005) Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420\u2013426","journal-title":"Trends Pharmacol Sci"},{"key":"1506_CR8","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.293.15.1861","volume":"293","author":"KM Flegal","year":"2005","unstructured":"Flegal KM, Graubard BI, Williamson DF, Gail MH (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293:1861\u20131867","journal-title":"JAMA"},{"key":"1506_CR9","unstructured":"Food and Drug Administration Endocrinologic and Metabolic Advisory (June 13, 2007) Briefing information, NDA 21-888 ZIMULTI (rimonabant)-Sanofi Aventis. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4306b1-fda-backgrounder.pdf (accessed March 13, 2008)"},{"key":"1506_CR10","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","volume":"102","author":"G Gobbi","year":"2005","unstructured":"Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620\u201318625","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1506_CR11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.299.10.1135","volume":"299","author":"OM Habayeb","year":"2008","unstructured":"Habayeb OM, Taylor AH, Finney M, Evans MD, Konje JC (2008) Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage. JAMA 299:1135\u20131136","journal-title":"JAMA"},{"key":"1506_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1524-4733.2007.00281.x","volume":"11","author":"C Hampp","year":"2008","unstructured":"Hampp C, Hartzema AG, Kauf TL (2008) Cost\u2013utility analysis of rimonabant in the treatment of obesity. Value Health 11:389\u2013399","journal-title":"Value Health"},{"key":"1506_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp068177","volume":"356","author":"P Hossain","year":"2007","unstructured":"Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the developing world\u2014a growing challenge. N Engl J Med 356:213\u2013215","journal-title":"N Engl J Med"},{"key":"1506_CR14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","volume":"194","author":"MA Huestis","year":"2007","unstructured":"Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194:505\u2013515","journal-title":"Psychopharmacology (Berl)"},{"key":"1506_CR15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/gut.2008.148791","volume":"57","author":"AA Izzo","year":"2008","unstructured":"Izzo AA, Camilleri M (2008) Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57:1140\u20131155","journal-title":"Gut"},{"key":"1506_CR16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrd2775","volume":"7","author":"D Jones","year":"2008","unstructured":"Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961\u2013962","journal-title":"Nat Rev Drug Discov"},{"key":"1506_CR17","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1038\/npp.2008.21","volume":"33","author":"Z Justinova","year":"2008","unstructured":"Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 33:2870\u20132877","journal-title":"Neuropsychopharmacology"},{"key":"1506_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"S Kathuria","year":"2003","unstructured":"Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76\u201381","journal-title":"Nat Med"},{"key":"1506_CR19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1503\/cmaj.070627","volume":"177","author":"B Foll Le","year":"2007","unstructured":"Le Foll B, George TP (2007) Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 177:1373\u20131380","journal-title":"CMAJ"},{"key":"1506_CR20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","volume":"312","author":"B Foll Le","year":"2005","unstructured":"Le Foll B, Goldberg SR (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875\u2013883","journal-title":"J Pharmacol Exp Ther"},{"key":"1506_CR21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","volume":"13","author":"B Foll Le","year":"2008","unstructured":"Le Foll B, Forget B, Aubin HJ, Goldberg SR (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13:239\u2013252","journal-title":"Addict Biol"},{"key":"1506_CR22","unstructured":"Merck (2008) Merck discontinues development of investigational medicine taranabant for obesity. http:\/\/www.merck.com\/newsroom\/press_releases\/research_and_development\/2008_1002.html"},{"key":"1506_CR23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299:1547\u20131560","journal-title":"JAMA"},{"key":"1506_CR24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"CL Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA 295:1549\u20131555","journal-title":"JAMA"},{"key":"1506_CR25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389\u2013462","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"1506_CR26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2826.2008.01693.x","volume":"20","author":"FJ Pavon","year":"2008","unstructured":"Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, Macias M, Goya P, de Fonseca FR (2008) Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20(Suppl 1):116\u2013123","journal-title":"J Neuroendocrinol"},{"key":"1506_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1360-0443.2005.01313.x","volume":"101","author":"P Reuter","year":"2006","unstructured":"Reuter P, Pollack H (2006) How much can treatment reduce national drug problems? Addiction 101:341\u2013347","journal-title":"Addiction"},{"key":"1506_CR28","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar2401","volume":"10","author":"D Richardson","year":"2008","unstructured":"Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10:R43","journal-title":"Arthritis Res Ther"},{"key":"1506_CR29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1360-0443.2008.02454.x","volume":"104","author":"NA Rigotti","year":"2009","unstructured":"Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y (2009) A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 104:266\u2013276","journal-title":"Addiction"},{"key":"1506_CR30","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc08-0386","volume":"31","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Hollander P, Chevalier S, Iranmanesh A (2008) SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31:2169\u20132176","journal-title":"Diabetes Care"},{"key":"1506_CR31","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194\u20131199","journal-title":"BMJ"},{"key":"1506_CR32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.physbeh.2007.04.013","volume":"91","author":"JD Salamone","year":"2007","unstructured":"Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91:383\u2013388","journal-title":"Physiol Behav"},{"key":"1506_CR33","unstructured":"Sanofi Aventis (2008) Sanofi-Aventis to discontinue all clinical trials with Rimonabant, Paris"},{"issue":"Suppl 1","key":"1506_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2826.2008.01681.x","volume":"20","author":"AJ Scheen","year":"2008","unstructured":"Scheen AJ (2008) CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 20(Suppl 1):139\u2013146","journal-title":"J Neuroendocrinol"},{"key":"1506_CR35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/187152708786927859","volume":"7","author":"M Scherma","year":"2008","unstructured":"Scherma M, Fadda P, Le Foll B, Forget B, Fratta W, Goldberg SR, Tanda G (2008a) The endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets 7:468\u2013481","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1506_CR36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1124\/jpet.108.142224","volume":"327","author":"M Scherma","year":"2008","unstructured":"Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaleddin I, Le Foll B, Justinova Z, Mikics E, Haller J, Medalie J, Stroik J, Barnes C, Yasar S, Tanda G, Piomelli D, Fratta W, Goldberg SR (2008b) Inhibition of anandamide hydrolysis by URB597 reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 327:482\u2013490","journal-title":"J Pharmacol Exp Ther"},{"key":"1506_CR37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","volume":"28","author":"M Soyka","year":"2008","unstructured":"Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 28:317\u2013324","journal-title":"J Clin Psychopharmacol"},{"key":"1506_CR38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.811992","volume":"119","author":"K Sugamura","year":"2009","unstructured":"Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, Nakayama M, Kaikita K, Obata T, Takeya M, Ogawa H (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119:28\u201336","journal-title":"Circulation"},{"key":"1506_CR39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/80577","volume":"3","author":"G Tanda","year":"2000","unstructured":"Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073\u20131074","journal-title":"Nat Neurosci"},{"key":"1506_CR40","volume-title":"The health consequences of smoking: a report of the surgeon general","author":"U.S. Department of Health and Human Services","year":"2004","unstructured":"U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the surgeon general. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA"},{"key":"1506_CR41","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Gaal Van","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389\u20131397","journal-title":"Lancet"},{"key":"1506_CR42","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","volume":"29","author":"LF Gaal Van","year":"2008","unstructured":"Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O (2008) Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 29:1761\u20131771","journal-title":"Eur Heart J"},{"key":"1506_CR43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1369-1600.2008.00109.x","volume":"13","author":"J Wiskerke","year":"2008","unstructured":"Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225\u2013238","journal-title":"Addict Biol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-009-1506-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-009-1506-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-009-1506-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:06:57Z","timestamp":1558642017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-009-1506-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s00213-009-1506-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,20]]}}}